Page 13 - The Next Pandemic: What's to Come?
P. 13
Eli Lilly, 27 Laboratory for the Modeling of
enzyme-linked immunosorbent Biological and Socio-technical
assay (ELISA), 24, 25 Systems (MOBS Lab), 9–11, 19
Erkenswick, Gideon, 45–46 Lucira Health, 24–25
Esperovax (biotech fi rm), 40
Manning, Jessica, 20–21
facial-recognition software, 13 Marathe, Madhav, 13
Food and Drug Administration, Matus, Mariana, 19
US (FDA), 21, 57 messenger RNA (mRNA)
technology, 7
Gates, Bill, 19 microneedle patches, 40–41
Gerngross, Tillman, 30 Middle East respiratory syndrome
Gillespie, Tom, 43 (MERS), 4–5
Global Immunological Mina, Michael, 16–18
Observatory (GIO), 17, 19 Misra, Vikram, 50
global travel, 4, 6 MOBS Lab. See Laboratory for
Global Virome Project (GVP), the Modeling of Biological and
46–48, 57 Socio-technical Systems
molecular clamp, 35
Hahn, Stephen, 27 monoclonal antibodies
Hatchett, Richard, 31 AstraZeneca’s version of, 28–29
Heritage Foundation (HF), 57 binding to coronavirus spike
HIV (human immunodefi ciency protein, 28
virus), 36 in prevention of coronavirus
Hoey, David, 41 infection, 30
home testing, 24–26 Regeneron treatment using,
Hyfe (smartphone app), 15 26–28
mosquito-borne illnesses, 5
infection prevention (IP), 29 Mulligan, Mark, 27
Inglesby, Thomas, 49 Musk, Elon, 34, 34
Internet of Everything (IoE),
11–12 nanobodies, 27
Iwen, Peter C., 21–22 National Center for Health
Statistics, 9
Jerome, Keith, 22 National Institutes of Health (NIH),
Johnson, Christine Kreuder, 46 23, 24
Nature (journal), 37
Kamal-Yanni, Mohga, 36 Nelson, Todd, 34
Kinsa Insights (database), 11 Nipah virus, 5, 48
Krammer, Florian, 23–24 Nobel, Yanthe, 42, 43, 44
59
